Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 11 min ago
Peer-reviewedCC BY-NCAlzheimer's & dementia (Amsterdam, Netherlands)

Stability of plasma pTau217/Aβ42 ratio with delayed blood processing.

  • Hana Mayfield1,2
  • Casey S John1,2
  • Jenae Pennington1,2
  • Riley E Kemna1,2
  • Maggie Kroeger1,2
  • Amitava Dasgupta3
  • Jeffrey M Burns1,2
  • Fanny M Elahi4
  • Melody Nelson3
  • Jill K Morris1,2
4 affiliations
  1. 1University of Kansas Medical Center Department of Neurology Kansas City Kansas USA.
  2. 2University of Kansas Alzheimer's Disease Research Center Fairway Kansas USA.
  3. 3University of Kansas Health System Department of Pathology and Laboratory Medicine Kansas City Kansas USA.
  4. 4Friedman Brain Institute Ronald M. Loeb Center for Alzheimer's Disease Icahn School of Medicine at Mount Sinai New York New York USA.
Read full textPDFDOICite

Abstract

Introduction

Blood-based biomarkers may improve access to Alzheimer's disease diagnosis, but use may be limited in clinics without on-site processing capability. We evaluated the stability of the plasma phosphorylated tau 217 (pTau217)/amyloid beta 42 (Aβ42) ratio after delayed whole-blood processing.Methods

We compared blood processed within 2 h or held at 4°C for approximately 24 or 48 h before centrifugation and analysis using the Fujirebio Lumipulse G1200. Stability was assessed using ordinary least squares regression, error index, Bland-Altman analysis, and Deming regression.Results

Correlations with the 2-h condition were high at both 24 and 48 h (R = 0.998). Both delayed conditions met prespecified regression and error-index criteria. Mean absolute percent error was 5.6% at 24 h and 9.8% at 48 h. Deming regression showed no constant bias, although proportional bias was observed at 48 h. No bias was observed for individual analytes for up to 48 h.Discussion

The pTau217/Aβ42 ratio in refrigerated whole blood remained stable for 24 h, with possible utility up to 48 h, supporting more flexible specimen-transport workflows.

Related

  1. Optimizing Lumipulse plasma pTau217/Aβ42 ratio cutpoints in an Asian cohort with high cerebrovascular disease burden
    J. R. Chong, A. T. Y. Yam, A. Toh +7
    medRxivPreprintCC BYFull textNeurologymedRxiv
  2. Biomarker Convert: a novel approach to transform plasma pTau217 results across immunoassay and mass spectrometry analytical platforms
    K. J. Quadrini, J. Aubrecht, F. Vernhes +9
    medRxivPreprintAll rights reservedFull textNeurologymedRxiv
  3. Brain-Derived pTau217 and Plasma Proteomic Profiles Across Cognitive and Dementia Groups in Congolese Older Adults
    J. N. Ikanga, S. S. Patel, T. E. Boots +13
    medRxivPreprintAll rights reservedFull textNeurologymedRxivPMC
  4. Plasma pTau217 and pTau231 predict progression to dementia in Parkinson’s disease: a prospective longitudinal study
    Cheng-Hsuan Li, Ting-Wen Cheng, Chin-Hsien Lin
    NPJ Parkinson's DiseasePeer-reviewedCC BY-NC-ND 4.0Full text1 citedPsychiatry & mental healthPMC
  5. Comparative analysis of plasma pTau217, NfL and eight modifiable risk scores for 11-year dementia prediction in the HUNT Study
    J. Stubs, E. M. Langballe, G. Livingston +7
    medRxivPreprintCC BYFull textNeurologymedRxiv

Cite

BibTeXRIS
BibTeX
@article{mayfield2026stability,
  title = {{Stability of plasma pTau217/Aβ42 ratio with delayed blood processing.}},
  author = {Hana Mayfield and Casey S John and Jenae Pennington and Riley E Kemna and Maggie Kroeger and Amitava Dasgupta and Jeffrey M Burns and Fanny M Elahi and Melody Nelson and Jill K Morris},
  journal = {Alzheimer's \& dementia (Amsterdam, Netherlands)},
  year = {2026},
  month = oct,
  doi = {10.1002/dad2.70517},
  url = {https://europepmc.org/article/MED/42908786},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - Stability of plasma pTau217/Aβ42 ratio with delayed blood processing.
AU  - Hana Mayfield
AU  - Casey S John
AU  - Jenae Pennington
AU  - Riley E Kemna
AU  - Maggie Kroeger
AU  - Amitava Dasgupta
AU  - Jeffrey M Burns
AU  - Fanny M Elahi
AU  - Melody Nelson
AU  - Jill K Morris
PY  - 2026
DA  - 2026/10/20
JO  - Alzheimer's & dementia (Amsterdam, Netherlands)
DO  - 10.1002/dad2.70517
UR  - https://europepmc.org/article/MED/42908786
AB  - Introduction  Blood-based biomarkers may improve access to Alzheimer's disease diagnosis, but use may be limited in clinics without on-site processing capability. We evaluated the stability of the plasma phosphorylated tau 217 (pTau217)/amyloid beta 42 (Aβ42) ratio after delayed whole-blood processing.Methods  We compared blood processed within 2 h or held at 4°C for approximately 24 or 48 h before centrifugation and analysis using the Fujirebio Lumipulse G1200. Stability was assessed using ordinary least squares regression, error index, Bland-Altman analysis, and Deming regression.Results  Correlations with the 2-h condition were high at both 24 and 48 h (R = 0.998). Both delayed conditions met prespecified regression and error-index criteria. Mean absolute percent error was 5.6% at 24 h and 9.8% at 48 h. Deming regression showed no constant bias, although proportional bias was observed at 48 h. No bias was observed for individual analytes for up to 48 h.Discussion  The pTau217/Aβ42 ratio in refrigerated whole blood remained stable for 24 h, with possible utility up to 48 h, supporting more flexible specimen-transport workflows.
SN  - 2352-8729
ER  -